Search results
Results From The WOW.Com Content Network
Here's what's going on, what you need to know, and what you should do.The cold, hard factsThe Financial Times is reporting that pharmaceutical giant Pfizer (NYS: PFE) Pfizer Losing Lipitor Patent ...
Pfizer's U.S. patent on Lipitor expired on 30 November 2011. [127] Initially, generic atorvastatin was manufactured only by Watson Pharmaceuticals and India's Ranbaxy Laboratories . Prices for the generic version did not drop to the level of other generics—$10 or less for a month's supply—until other manufacturers began to supply the ...
The company lost U.S. patent protection for blockbuster cholesterol drug Lipitor and heart burn drug Protonix in 2011. Pfizer (NYS: PFE) careened off the patent cliff in more spectacular fashion ...
Pfizer has been no stranger to the kind of damage that blockbuster drug patent expirations can inflict. The company's high-flying cholesterol fighter, Lipitor, has struggled since losing its ...
L-Day is upon us. That thud you just heard was billions of dollars of Lipitor sales heading over the patent cliff. Pfizer (NYS: PFE) no longer has exclusivity on the drug as of today. We've known ...
Pfizer Inc. (/ ˈ f aɪ z ər / FY-zər) ... (LDL-C) than the other statin drugs. Upon its patent expiration in 2011, Lipitor was the best-selling drug ever, with ...
It could have been worse. A lot worse. Sales of Pfizer's (NYS: PFE) Lipitor fell 25% in the fourth quarter after losing U.S. patent protection in November, but overall revenue fell just 4%. Being ...
On 5 December 2010, [4] [1] when Read "took over from Jeffrey Kindler as Pfizer’s CEO, the drug firm–the world’s largest–was facing the impending patent expiration of Lipitor, the bestselling drug ever made, and the utter failure of one of the most lavishly funded research laboratories on the planet to develop much of anything."